S/MARter Immunotherapies
Our Mission
Immunotherapies have revolutionized cancer therapies during the last decade, in a number of cases practically curing previously uncurable cancers.
However, the majority of cancer patients still do not benefit from this revolution.
Tcelltech - founded by team of clinicians and scientists from the German Cancer Research Center DKFZ - has developed technology platforms wich can overcome some of the fundamental challenges and limitations, like manufacturing complexity and cost or suitable target identification and targeting moiety generation, currently prohibiting the success of immunotherapies for a larger number of patients.
We believe that our platforms will significantly improve immunotherapies for cancer and other deseases.
The Team
Founder, CEO
Prof Dr Michael Platten
Michael is Chairman of the Department of Neurology at the Medical Faculty Mannheim (UMM, part of Heidelberg University), and Professor of Neuroimmunology and Brain Tumor Immunology at the DKFZ. He is consistently rated in the top 1% in his field worldwide. Recently, Michael was awarded the German Cancer Award (alongside BioNTech’s Ugur Sahin) for his achievements in cancer research.
Founder, Research
Dr Ed Green
Ed is a permanent staff scientist at the DKFZ, and inventor of numerous patents in molecular biology, bioinformatics and high throughput screening that underpin our selecTCR personalised oncology pipeline. Ed’s science has been published extensively in top scientific journals.
Ed’s focus is on scaling up and further developing Tcelltech’s pipelines to reach more patients sooner.
Founder, Vector Technology & Manufacturing
Dr Richard Harbottle
Richard leads the DKFZ’s DNA Vector research group, with over three decades of experience in the field of vector development, and gene and cell therapy. Richard is a co-inventor on numerous vector and SMAR technology patents and serves as Tcelltech’s main point of contact to industry, having longstanding collaborations with leading gene therapy companies in the field such as MaxCyte, Miltenyi, Lonza and Nature Technologies.
Co-Founder, General Counsel
Dr Jochen Dieselhorst
Jochen has been a partner at the international law firm Freshfields Bruckhaus Deringer for over twenty years, mainly focusing on international licensing, collaborations and M&A in the biotech and pharma industry. He has led the German healthcare sector group of Freshfields for many years and brings a vast amount of experience in deal-making in the biotech sector.
Jochen’s broad experience and skills have been crucial for Tcelltech in the negotiations of the spin-off from DKFZ. Moving forward, Jochen’s expertise will be critical in leveraging Tcelltech’s IP in license and collaboration agreements.
Co-Founder, Finance
Dr Mathias Turwitt
Mathias co-founded and led a mid-cap private equity company managing EUR 370m of assets from international institutional investors over multiple funding rounds. Besides investing in successful Mittelstand companies and being a member of the investment committee, he was also the CFO.
Mathias brings a wealth of experience, especially in business strategy, value creation and fundraising to the Tcelltech team. Within our team, he will focus on finance and reporting.
Business Development Vector Technology
Dr Fritz Rudert
Fritz has more than 30 years of biopharma industry experience. He built up and headed research business development and IP departments at a number of biotech companies (Morphosys, Genesis, Xerion) and, through his consultancy FHR Consult, has supported many international biotech and pharma clients in licensing, financing, strategy and CMC projects.
Fritz' focus at Tcelltech is on outlicensing our nanoSMAR technology to interested parties for applications like cell and genetherapy and stem cells.
© 2025 Tcelltech GmbH. All rights reserved.
Wir benötigen Ihre Zustimmung zum Laden der Übersetzungen
Wir nutzen einen Drittanbieter-Service, um den Inhalt der Website zu übersetzen, der möglicherweise Daten über Ihre Aktivitäten sammelt. Bitte überprüfen Sie die Details in der Datenschutzerklärung und akzeptieren Sie den Dienst, um die Übersetzungen zu sehen.